Who to call at Inhibitor Therapeutics, Inc., and when
Fundz watches for the moments Inhibitor Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Inhibitor Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Inhibitor Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Inhibitor Therapeutics, Inc.. With Fundz connected, it knows.
Inhibitor Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
hedgepathpharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Inhibitor Therapeutics entered a performance-based master services agreement with Frameshift Management, Inc. on October 21, 2025, for biostatistics, regulatory, business development, and strategic consulting on its basal cell carcinoma programs in Gorlin's syndrome, and its board approved a 2025 Equity Incentive Plan the same day. The consultant's compensation is tied to performance, with unvested equity vesting only after specified requirements are met.
Key Takeaways
The consulting agreement with Frameshift Management covers biostatistics, regulatory, business development, and strategic support for the company's Gorlin's syndrome basal cell carcinoma programs.
The consultant's program will use the company's proprietary new itraconazole formulation, tying the engagement directly to a core pipeline asset.
3 more takeaways
Related Filings (4)
4 more filings from Inhibitor Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Inhibitor Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.